David Anderson, MD
Sleep Medicine · Great Falls, MTNPI 1063413789
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,809 of the $5,600 with a category attached, or 85.9%. It is spread thinly across 31 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,739 and has fallen 89.1% since, to $189 in 2025.
Across 250 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$913
- AstraZeneca$882
- GSK$594
- Mallinckrodt Hospital Products Inc.$524
- Harmony Biosciences LLC$356
- Boehringer Ingelheim$352
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,80986%
- Education$79014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 32 | $913 |
| AstraZeneca | 38 | $882 |
| GSK | 26 | $594 |
| Mallinckrodt Hospital Products Inc. | 12 | $524 |
| Harmony Biosciences LLC | 17 | $356 |
| Boehringer Ingelheim | 18 | $352 |
| Merck | 11 | $310 |
| Bayer | 11 | $226 |
| Mylan Specialty L.p. | 11 | $185 |
| Novartis | 10 | $172 |
| Grifols USA, LLC | 9 | $132 |
| Johnson & Johnson(2 entities) | 9 | $127 |
| Jazz Pharmaceuticals Inc. | 2 | $117 |
| Genentech USA, Inc. | 7 | $89 |
| Amgen | 5 | $83 |
| United Therapeutics Corporation | 7 | $76 |
| Resmed Corp | 1 | $58 |
| Sunovion Pharmaceuticals Inc. | 4 | $50 |
| Advanced Respiratory, Inc | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Philips North America LLC | 1 | $43 |
| Mallinckrodt Enterprises LLC | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Insmed, Inc. | 2 | $25 |
| Veran Medical Technologies, Inc. | 2 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Pfizer | 1 | $18 |
| Medtronic | 1 | $15 |
| Covidien LP | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few sleep medicine providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $634,952 |
| WakixPitolisant Hcl | 15 | $230,492 |
| OpsumitMacitentan | 17 | $211,408 |
| AdempasRiociguat | 13 | $176,193 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 119 | $101,277 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $76,649 |
| Pirfenidone | 17 | $26,908 |
| Spiriva RespimatTiotropium Bromide | 33 | $18,393 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $15,513 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $14,672 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $12,070 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,626 |
| EliquisApixaban | 11 | $9,464 |
| BelsomraSuvorexant | 17 | $9,050 |
| Arnuity ElliptaFluticasone Furoate | 17 | $5,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $352 | $668,858112 claims |
| Harmony Biosciences LLCWakix | $356 | $230,49215 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $913 | $211,40817 claims |
| BayerAdempas | $226 | $176,19313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $882 | $117,477177 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $594 | $96,382152 claims |
| PfizerEliquis | $18 | $9,46411 claims |
| MerckBelsomra | $310 | $9,05017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sleep medicine providers in Montanaon file to place this against a meaningful peer group, so we don't.
Other sleep medicine in Great Falls
- Timothy RouxGreat Falls$602
- Kelley ShippeyKalispell$8K
- Deborah HoffmanKalispell$4K
- Roy KohlerBillings$2K
- Ahmed RashwanMissoula$2K
- Rodolfo SocaBozeman$1K
- Kurt KubickaHelena$335
- Sowmini OommanBozeman$145
- Farnaz AbbasimoradiBillings$139
- Frederick ZellerBillings$26
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.